Abstract:Cytotoxic CD8(+) T cells are the main focus of efforts to understand anti-tumor immunity and immunotherapy. The adoptive transfer of tumor-reactive cytotoxic CD8(+) T lymphocytes expanded and differentiated in vitro has long been considered the primary strategy in adaptive anti-tumor immunity, however, the majority of the transferred tumor antigen-specific CD8(+) T cells differentiated into CD39(+)CD69(+) exhausted progenies, limiting its effects in repressing tumor growth. Contrarily, less attention has been addressed to the role of CD4(+) T cells during tumorigenesis. Using a mouse model of metastatic melanoma, we found that transferring tumor-specific CD4(+) T cells into recipients induces substantial regression of the established metastatic tumors. Notably, in vitro activated CD4(+) T cells developed into cytotoxic CD4(-) T cells in vivo and get exhausted gradually. The blockade of PD-L1 signaling resulted in an expansion of tumor specific CD4(+) T cells, which could better control the established metastatic melanoma. Moreover, the tumor-specific memory CD4(+) T cell can prevent mice from tumor metastasis, and the tumor-specific effector CD4(+) T cells can also mitigate the established metastatic tumor. Overall, our findings suggest a novel mechanism of CD4(+) T cells in curtailing tumor metastasis and confirm their therapeutic role in combination with PD-L1 blockade in cancer immunotherapy. Hence, a better understanding of cytotoxic CD4(-) T cell-mediated tumor regression could provide an alternative choice for patients exhibiting suboptimal or no response to CD8(+) T cell-based immunotherapies.

The outstanding antitumor capacity of CD4<SUP>+</SUP> T helper lymphocytes

The Outstanding Antitumor Capacity of CD4+ T Helper Lymphocytes.

Genetically engineered T cells for cancer immunotherapy

CD4+ T cells in antitumor immunity

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Roles of CD4+ T cells as mediators of antitumor immunity

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Tumor-Specific CD4<SUP>+</SUP> T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4<SUP>-</SUP> T Cells

Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4– T Cells

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells

CD4+ T cell help in cancer immunology and immunotherapy

Identification of human CD4+ T cell populations with distinct antitumor activity

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Activation of Endogenous CD4 T Cells Stimulates Favorable Immunologic Changes in the Tumor Milieu and Enhances the Antitumor Effect of Lentivector Immunization (48.15)

CD4+ T cells help myeloid-mediated killing of immune-evasive tumors

Cytotoxic CD4+ T cells in chronic viral infections and cancer